We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 26, 2018

Adjuvant Pembrolizumab vs Placebo in Resected Stage III Melanoma

The New England Journal of Medicine


Additional Info

The New England Journal of Medicine
Adjuvant Pembrolizumab Versus Placebo in Resected Stage III Melanoma
N. Engl. J. Med 2018 Apr 15;[EPub Ahead of Print], AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, A Haydon, M Lichinitser, A Khattak, MS Carlino, S Sandhu, J Larkin, S Puig, PA Ascierto, P Rutkowski, D Schadendorf, R Koornstra, L Hernandez-Aya, M Maio, AJM van den Eertwegh, JJ Grob, R Gutzmer, R Jamal, P Lorigan, N Ibrahim, S Marreaud, ACJ van Akkooi, S Suciu, C Robert

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading